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REVIEW
A Toll for lupus
H-J Anders*
Medical Policlinic, Ludwig-Maximilians-University, Munich, Germany
Toll-like receptor (TLR)-9 recognizes CpG motifs in microbial DNA. TLR9 signalling stimulates
innate antimicrobial immunity and modulates adaptive immune responses including autoimmunity
against chromatin, e.g., in systemic lupus erythematosus (SLE). This review summarizes the
available data for a role of TLR9 signalling in lupus and discusses the following questions that
arise from these observations: 1) Is CpG-DNA/TLR9 interaction involved in infection-induced
disease activity of lupus? 2) What are the risks of CpG motifs in vaccine adjuvants for lupus
patients? 3) Is TLR9 signalling involved in the pathogenesis of lupus by recognizing self
DNA? Lupus (2005) 14, 417–422.
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Introduction
Lupus represents a number of different pathophysiolo-
gical and clinical syndromes that share autoimmunity
against particles of self DNA. DNA autoimmunity
develops either from genetic or yet undefined
environmental factors, or a combination of both. The
latter involves the general problem of each organism to
keep the balance between tolerance to the self and to
maintain immunity to the foreign. Lupus teaches us,
that under normal conditions, tolerance to self DNA is
maintained by a number of mechanisms. Loss of
tolerance to self DNA occurs when genetic or external
factors lead to a functional blockade of such
mechanisms. In lupus, autoimmune tissue injury is
thought to be mediated by immune complexes that
contain nucleosomes or other chromatin-containing
particles. These immune complexes are recognized
through Fc receptors and subsequent complement
activation. The immunostimulatory effects of the
chromatin itself remained poorly defined.
The recognition of the cytosine-guanosine dinucleo-
tide as the stimulatory motif in bacterial DNA, a decade
ago,1 has raised enormous research activities aiming to
unravel the immunological properties of DNA sequence
elements. This review provides an overview about the
immunobiology of such DNA sequence elements and
discusses several issues that link these data to the
pathogenesis of lupus (Table 1). Further questions that are
discussed include: 1) Is CpG-DNA involved in infection-
induced disease activity of lupus? 2) What are the risks of
CpG motifs in vaccine adjuvants for lupus patients? 3) Is
the recognition of CpG motifs in self DNA involved in
the pathogenesis of lupus?
CpG-DNA is an ancient pathogen-associated
molecular pattern that causes immunity
DNA is traditionally thought to be a condensed medium
of information that allows reproduction and that
encodes for a certain phenotype. However, DNA has
additional functions. Only a decade ago Arthur M
Krieg in Dennis M Klinman’s laboratory first described
the cytosine-guanosine dinucleotide motif as the
substrate of the immunostimulatory effects of bacterial
DNA.1 However, CpG motifs are present in DNAs of
all kinds of microbes, better to say, in all species.2 The
discovery of other microbial ligands that serve as
pathogen-associated molecular pattern (PAMPs)
including lipopolysaccharides, peptidoglycans, RNAs
or lipopeptides suggest that the recognition of PAMPs
provide signals to the eukariont about its microbial
environment very early during evolution.3 Accumulat-
ing data show that among other microbial nucleic acids
bacterial CpG-DNA is a potent activator of innate
antimicrobial immunity and a modulator of adaptive
immune responses. Bacterial CpG-DNA was first
described as a B cell mitogen.1 In addition, immune
complexes that contain unmethylated CpG-DNA, have
been demonstrated to induce T cell-independent
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activation, proliferation, and autoantibody production
by B-cells.4 In fact, covalent linkage of CpG-DNA to an
antigen provides a powerful signal for the activation of
other antigen-presenting cells, including dendritic cells
and, in mice, macrophages.5 Exposure to CpG-DNA
induces antigen-presenting cells to secrete Th1
cytokines, i.e., IL-12 or IFN-g.6 Subsequent T cell or
B cell responses are modulated towards a Th1-type
response which can be therapeutic in Th2-type diseases
like asthma and atopy7 and that provide the rationale for
using CpG DNA as a vaccine adjuvant.8 However, a
number of studies suggest that the immunostimulatory
effects of CpG-DNA can initiate or unfavourably
modulate autoimmunity (Table 1). For example,
exposure to CpG-DNA aggravates various types of
chronic autoimmune tissue injury, e.g., arthritis,
encephalitis or glomerulonephritis.9 – 11 Furthermore,
CpG-DNA-induced secretion of IL-6 by dendritic cells
blocks the inhibitory effect of regulatory T cells leading
to uncontrolled proliferation of autoreactive T cells.12
This mechanism may have important implications on
the role of CpG-DNA in autoimmunity.13 At high doses
CpG-DNA-induced activation of TLR9 can lead to
toxic shock.14 Repeated injections with CpG-DNA
cause liver cell apoptosis, systemic cytokine release,
lymphoproliferation, and functional immunosuppres-
sion.15 Thus, CpG-DNA has potent immunomodula-
tory functions, that may well be involved in the
pathogenesis of lupus.
CpG-DNA signals through Toll-like receptor
(TLR)-9
PAMPs need to be recognized by appropriate pattern
recognition receptors. In the year 2000, Shizuo Akira’s
group identified a Toll-like receptor, TLR9, to
exclusively recognize CpG-DNA.14 TLR9-deficient
mice did not respond to CpG-DNA and cells isolated
from these mice remained unresponsive upon stimu-
lation with CpG-DNA in vitro.14 TLR9 belongs to the
subgroup of nucleic acid-specific TLRs that also
include TLR3 (ligand: double-stranded viral RNA)
and TLR7/8 (ligand: single-stranded viral RNA)
which share genetic and biological homologies. TLR9
turned out to be expressed only by a small set of
immune cells. In humans, TLR9 expression is
restricted to B cells and to plasmocytoid dendritic
cells, whereas in mice TLR9 is expressed on additional
antigen presenting cells including monocyte/macro-
phages and myeloid dendritic cells.5 In these cells
TLR9 is located in the endoplasmatic reticulum.16
After uptake extracellular material is processed in
endosomes which induces TLR9 redistribution from
the endoplasmatic reticulum to late endosomes.16
Interestingly, the stimulatory effect of CpG-DNA on
the cellular uptake of CpG-DNA-conjugates is
independent of TLR9, suggeting another yet undefined
DNA receptor.17 CpG-oligodeoxyribonucleotides
(ODN) form aggragates that allow direct binding to
TLR9, a process that is pH dependent,18 – 20 as
chloroquine and other inhibitors of endosomal
acidification are potent inhibitors of TLR9 activation
by CpG-DNA.5,19 This finding possibly represents
the previously unknown molecular mechanism for the
efficacy of chloroquine treatment in lupus. The
interaction of TLR9 with CpG-DNA leads to
recruitment of the adaptor protein myeloid differen-
tiation primary-response protein 88 (MyD88) from the
cytosol to the outer endosomal membrane where it
interacts with the intracellular Toll-interleukin 1
receptor (TIR) domain of TLR9 (Figure 1). Through
activating interleukin-1 receptor-associated kinase
(IRAK)-4, TNF receptor associated factor (TRAF)-6,
and interferon regulatory factor-8/IFN consensus
sequence binding protein TLR9 signalling finally
activates NF-kB.9,21,22 After translocation into the
nucleus NF-kB induces the expression of many
proinflammatory genes including TNFa, IL-6,
IL-1b, IL-8, IL-12, IL-18, as well as CC- and CXC-
chemokines.23 The fact that different classes of
CpG-ODN have been shown to cause different
immunostimulatory activities suggests additional yet
unknown modulators of TLR9-induced signal
transduction.24,25
CpG-DNA/TLR9 interaction modulates innate
and adaptive immunity in lupus
The potential of CpG-DNA for activating B cells and
plasmocytoid dendritic cells suggest that TLR9 might
play a role in the pathogenesis of lupus.26,27 In fact,
Table 1 Mechanisms that link CpG-DNA to the pathogenesis
of lupus
B cells
Bacterial DNA is a B cell mitogen Ref. 1
CpG motifs in chromatin particles crosslink the BCR to TLR9
which leads to T cell independent B cell proliferation and
autoantibody production
Ref. 4
Dendritic cells
CpG-DNA induces dendritic cells to produce Th1 cytokines Ref. 6
CpG-DNA can induce dendritic cells to produce IL-6 Ref. 12
T cells
Known triggers of SLE lead to hypomethylation of CpG motifs
in self DNA
Ref. 35
IL-6 blocks the inhibitory function of regulatory T cells Ref. 12
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B cells isolated from MRLlpr/lpr mice with lupus-like
disease, produce large amounts of autoantibodies when
exposed to immune complexes that contain CpG-
DNA.4 Autoreactive B-cells from these mice recognize
the IgG part of the immune complex by their surface
BCR, then internalize the immune complex which
exposes CpG-DNA to TLR9 in the endosomal
compartment.28 These mechanisms may also apply
in vivo, because autoimmune MRLlpr/lpr mice injected
with bacterial CpG-DNA produce large amounts of
DNA autoantibodies29 in association with increased
MHC II expression on B cells isolated from spleens of
these mice (unpublished observation). The avidity of
DNA autoantibodies present in MRLlpr/lpr mice and
those induced by unmethylated CpG-DNA is compar-
able.30 Systemic exposure to bacterial CpG-DNA can
induce the production of DNA autoantibodies in
nonimmune mice.31 Furthermore, CpG-DNA has a
strong adjuvant effect on DNA autoantibody pro-
duction in mice that have been exposed to vertebrate
DNA.31 These data support the hypothesis that in
systemic lupus erythematosus (SLE) exposure to
bacterial DNA, e.g., during bacterial infection,
provides a strong signal for enhanced DNA autoanti-
body production. The presence of unmethylated
CpG-DNA in immune complexes facilitate their
intracellular uptake and exposure to TLR9 in
endosomes via IgG/BCR interaction in B cells.28,32
As outlined above, TLR9 is expressed in additional
leukocyte subsets which may cause other immune
effects in addition to B cell activation after exposure to
CpG-DNA in SLE. Thus, we determined the
distribution of rhodamin-labelled CpG-DNA after
injection into 16-weeks old autoimmune MRLlpr/lpr
mice and nonautoimmune MRL wild-type mice.29 In
MRLlpr/lpr mice CpG-DNA localized to infiltrating F4/
80 positive macrophages and CD11c positive dendritic
cells in the glomerular and tubulointerstitial compart-
ment of nephritic kidneys. By contrast, in healthy MRL
wild-type mice CpG-DNA did not localize to the
kidney. The distribution of CpG-DNA was consistent
with TLR9 protein expression in monocytic inflamma-
tory cell infiltrates upon immunostaining. MRLlpr/lpr
mice treated with CpG-DNA every other day from
Figure 1 DNA recognition through TLR-9. TLR9 is located in the ER and merges to intracellular endosomes upon uptake of micro-
organisms or immune complexes. TLR9 signals exclusively through the MyD88–IRAK4–TRAF6–IRF-8 pathway and subsequently induces
nuclear translocation of NF-kB. NF-kB-dependent gene expression includes many proinflammatory mediators, e.g., cytokines and chemokines.
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week 16 to 18 of age showed marked increase in renal
expression of NF-kB-dependent CC-chemokines
which localized to areas of TLR9 positive cells. Thus,
systemic exposure to bacterial CpG-DNA involves
activation of TLR9 positive cells in preexisting
inflammatory cell infiltrates, e.g., in lupus nephritis.
Enhanced DNA autoantibody production and activation
of tissue monocytes, occured in parallel and this was
associated with severe aggravation of lupus nephritis.29
These data support the hypothesis that in SLE
intercurrent bacterial infections can trigger disease
activity by circulating bacterial CpG-DNAvia TLR9 on
autoreactive B cells and selected tissue monocyte
populations. In the latter TLR9 activation can add on
the TLR9-independent stimulation that is provided by
the immune complex itself.33
Infections might aggravate lupus also through other
TLRs. In fact, in a similar experimental set up we found
that viral double-stranded RNA induced marked
autoimmune disease activity in MRLlpr/lpr mice
(manuscript in revision). However, this was mediated
by different mechanisms, because TLR3 has a different
expression profile as compared to TLR9. For example,
B cells lack TLR3 and double-stranded RNA fails to
activate B cells and DNA autoantibody production in
MRLlpr/lpr mice. In contrast, TLR3 is expressed on
glomerular mesangial cells and double-stranded RNA
induces mesangials cells to produce cytokines and
chemokines, known to aggravate glomerular inflam-
mation (unpublished data).
Does TLR9 recognize self-DNA?
Chromatin-containing particles are major antigens in
lupus. Thus, the question arises whether TLR9-related
recognition of CpG motifs in self DNA is involved in the
pathogenesis of SLE? From the early times of evolution
a Toll receptor that recognizes microbial DNA required
mechanisms that prevent self DNA recognition in
order to avoid autoimmunity. In vertebrates three
such mechanisms have been identified. These include
the methylation state of CpG motifs, the frequency of
CpG motifs, and inhibitory DNA sequences.
Methylation state of CpG motifs
Microbial DNA is unmethylated as microbes lack
methyltransferases. Methylation reduces the immunos-
timulatory effects of bacterial DNA34 and treatment
with CpG methylase inactivates CpG-ODN.1 In
vertebrates CpG motif cytosines are 70–80% methyl-
ated which is thought to contribute to the lack of
immunostimulatory activity of their DNA.35 In fact,
hypomethylation of self DNA can be associated with
autoimmunity and lupus,36 indicating that hypomethy-
lated CpG motifs in self DNA may contribute to the
pathogenesis of lupus. For example, inhibiting DNA
methylation in mature T cells induces LFA-1 positive
autoreactive T cells that mediate DNA autoantibody
production.37 Known triggers of lupus-like syndromes
including UV light, hydralazine, and procainamide
inhibit the activity of DNA methyltransferases and
induce autoreactive T cell subsets.37 Patients with
active lupus have decreased enzyme activity of DNA
methyltransferases, lower rates of genomic methylated
cytosine nucleotides, and increased levels of circulating
hypomethylated DNA.38 Patients with active lupus also
have increased numbers of autoreactive T cells that
overexpress LFA-1.38 These data support the hypoth-
esis that DNA methylation provides tolerance to self
DNA and that impaired DNA methylation can be
associated with lupus disease activity, possibly through
the recognition of CpG motifs via TLR9.
Frequency of CpG-motifs
Vertebrate DNA that has been completely demethylated
still shows only weak stimulatory activity as compared
to bacterial DNA.39 These data argue for additional
factors that protect self-DNA from activating immunity.
Several studies have addressed this issue by compara-
tive genome analysis for the frequency of CpG-motifs
in different species. For example, stimulatory CpG
motifs are present in vertebrate genomes but at only a
frequency of 20% of random frequency.40 By contrast,
CpG motifs are overrepresented in E. coli DNA39
supporting the idea that during evolution of species
stimulatory CpG motifs were negatively selected in
vertebrate DNAs and positively selected in bacterial
DNA. This would explain why similar amounts of
unmethylated bacterial DNA activate TLR9 positive
human cells to a greater extent than demethylated
human DNA.
Inhibitory DNA sequences
In their search for ODN that have optimal stimulatory
activity several groups detected sequence motifs that
inhibit CpG-DNA-induced effects. Screening the
mouse and E. coli genomes for the frequency of such
inhibitory DNA sequences showed that such inhibitory
DNA sequence elements are present at a high frequency
in the mouse genome and underrepresented in the
E. coli genome.39 Obviously, the ratio of stimulatory
and inhibitory sequence elements regulates the
immunomodulatory potential of DNA. Following this
hypothesis human self DNA that includes a high
number of inibitory sequence elements would neutralize
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the small number of (methylated) CpG motifs. In view
of TLR9 recognizing CpG motifs this would represent
another mechanism to discriminate self DNA from
microbial DNA, the latter characterized by a high
number of (unmethylated) CpG motifs in the presence
of a small number of inhibitory sequences.
Stimulatory and inhibitory DNA sequence
motifs can modulate immunity
ODNs that include either stimulatory, inhibitory or inert
sequence elements may therefore represent an interest-
ing tool for studying the immunomodulatory functions
of DNA in vitro and in vivo but may also provide new
questions for patients with lupus. 1) Will therapeutic
use of CpG-DNA for other indications cause disease
activity in SLE patients? 2) Does CpG-DNA therapy
cause drug-induced lupus? 3) Can we treat lupus with
ODN containing inhibitory sequence elements?
Safety of CpG-ODN therapy in SLE
CpG-ODN are currently in clinical trials for the
treatment of cancer, atopy and as vaccine adju-
vants.8,41,42 Our findings with CpG-ODN in murine
SLE raise considerable concern about the safety of
CpG-ODN therapy in SLE patients.29 Exposure to
unmethylated immunostimulatory CpG-ODN may
cause similar aggravation of disease in SLE patients
as CpG-ODN in autoimmune MRLlpr/lpr mice. These
data are supported by an increasing number of reports
showing that CpG-ODN can aggravate other animal
models of chronic autoimmune tissue injury, e.g.,
arthritis, encephalitis or glomerulonephritis.9 – 11 How-
ever, toxicity may be related to the dose, treatment
intervals, and the route of administration of CpG-ODN.
All experimental data showing disease aggravation are
derived from studies that used repeated intraperitoneal
injections of CpG-ODN. Topical application or single
vaccination regimen might have less effects on
preexisting autoimmunity.
Drug-induced lupus
The ability of bacterial DNA to induce DNA
autoantibodies in vitro and in vivo suggests that
CpG-ODN therapy might trigger drug-induced lupus.
Clinical or serological signs of drug-induced lupus did
not occur in a recently reported trials that applied CpG-
DNA as a vaccine adjuvant.41,43 However, in view of
the history of the reported induction of DNA
autoantibodies with anti-TNFa treatment regimen
that increased from ‘never observed’ in phase I trials to
56% in more recent studies,44 one should await studies
with higher numbers of patients before a firm
statement upon the potency of CpG-ODN to induce
lupus-like syndromes can be made.
Treating lupus with inhibitory DNA
As outlined above inhibitory DNA sequences may
suppress the stimulatory effects of CpG motifs in
human self DNA. Based on in vitro studies showing
that CpG-induced immunity can be blocked with ODN
containing inhibitory DNA motifs the hypothesis of
targeting SLE with such ODN evolves. We have tested
this hypothesis and found that inhibitory ODN can
effectively block CpG-ODN-induced effects in vivo
(unpublished observation). Whether the onset or
progression of spontaneous SLE can be prevented by
injections of inhibitory ODN is currently under study.
Only the latter would argue for a role of TLR9 in the
pathogenesis of lupus. In that case developing specific
small molecule TLR9 antagonists would represent an
interesting perspective for the treatment of SLE.
Summary
Lupus is characterized by autoimmunity against self
DNA. The recognition of TLR9 as an ancient receptor
that recognizes unmethylated CpG-DNA raises a set of
questions of its role in the pathogenesis of SLE. At
present there is evidence that TLR9 signaling is
involved in the lupus disease activity that is triggered by
unmethylated microbial DNA, e.g., during intercurrent
microbial infections that trigger lupus flares. In contrast
to microbial DNA, CpG motifs in self DNA are
suppressed by several mechanisms, which provide
tolerance to self DNA under normal conditions.
Whether lupus pathogenesis involves TLR9-dependent
recognition of hypomethylated self DNA is still
unclear, although a number of studies provide data
that support this hypothesis. If impaired tolerance to
self DNA will turn out to involve TLR9, then TLR9
may become an interesting target for therapeutic
intervention in lupus.
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